<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01033344</url>
  </required_header>
  <id_info>
    <org_study_id>CP005</org_study_id>
    <nct_id>NCT01033344</nct_id>
  </id_info>
  <brief_title>Cat-PAD Exposure Chamber Study</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled Study to Evaluate Two Treatment Regimens of Cat-PAD in Cat Allergic Subjects Following Challenge to Cat Allergen in an Environmental Exposure Chamber</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adiga Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cetero Research, San Antonio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with
      allergic rhinoconjunctivitis and/or asthma. Cat-PAD is a novel, synthetic, allergen-derived
      peptide desensitising vaccine, currently being developed for the treatment of cat allergy.

      This study will look at the efficacy, safety and tolerability of two doses of Cat-PAD in cat
      allergic subjects following challenge to cat allergen in an EEC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed as a randomised, double-blind, placebo-controlled, parallel group
      study to evaluate the safety and tolerability of Cat-PAD in cat allergic subjects with
      allergic rhinoconjunctivitis,subjects may also have controlled asthma. The efficacy of
      Cat-PAD will be explored in subjects using an(Environmental Exposure Chamber)EEC.

      The study will consist of 3 study periods. In Period 1, Screening will be performed up to a
      maximum of 12 weeks before randomisation and may consist of one or two visits to the clinic,
      at the Investigator's discretion. Baseline Challenge will consist of 4 visits to the EEC at
      least 3 days before randomisation.

      In Period 2, subjects in each cohort complying with the inclusion/exclusion criteria will be
      randomised to one of three groups and will receive treatment every 2 weeks (Â±2 days) for 14
      weeks.

      In Period 3, Post Treatment Challenge will consist of 4 visits to the EEC 18-22 weeks after
      the first administration in the treatment period and assessments will be performed identical
      to those at the baseline challenge. Follow-up will be conducted 3-10 days after PTC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Rhinoconjunctivitis Symptom Score</measure>
    <time_frame>0 and 18-22 weeks after start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom scores for ocular and nasal symptoms</measure>
    <time_frame>0 and 18-22 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acoustic Rhinometry</measure>
    <time_frame>0 and 18-22 weeks after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cat Specific IgE</measure>
    <time_frame>At 0 weeks and at follow up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>During study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Cat Allergy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Solution resembling active solution but without peptides</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cat-PAD dose group 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cat-PAD Dose group 2</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intradermal injection 1x8 administrations 2 weeks apart</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cat-PAD</intervention_name>
    <description>Intradermal injection 1x8 administrations 2 weeks apart</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cat-PAD</intervention_name>
    <description>Intradermal injection, 1x8 administrations 2 weeks apart, alternating active and placebo</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18-65 years

          -  Minimum 1-year history of rhinoconjunctivitis on exposure to cats. (Subjects may also
             have controlled asthma)

          -  Positive skin prick test to cat allergen with a wheal diameter at least 3mm larger
             than that produced by the negative control

          -  Minimum qualifying rhinoconjunctivitis symptom scores

        Exclusion Criteria:

          -  &quot;Partly controlled&quot; and &quot;uncontrolled&quot; asthma

          -  History of anaphylaxis to cat allergen

          -  FEV1 of less than 70% of predicted

          -  Subjects who cannot tolerate baseline challenge in the EEC

          -  Treatment with beta-blockers,Alpha-adrenoceptor blockers, Tranquillizers or
             psychoactive drugs

          -  A history of any significant disease or disorder (e.g. cardiovascular, pulmonary,
             gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic,
             neoplastic/malignant, psychiatric, major physical impairment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepen Patel, MD, CCF</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cetero Research, San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cetero Research</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W 1N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2009</study_first_submitted>
  <study_first_submitted_qc>December 15, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2009</study_first_posted>
  <last_update_submitted>September 30, 2010</last_update_submitted>
  <last_update_submitted_qc>September 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr Rod Hafner</name_title>
    <organization>Circassia Ltd</organization>
  </responsible_party>
  <keyword>Cat allergy</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <keyword>Exposure chamber</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Cat-PAD</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

